Chiffres calculés à partir des déclarations réglementaires officielles — .
Détentioninitiés 25.37% · institutions 2.69%
En EUR · au Oct 19, 2026
Interroger la machine
Recherchez et comparez les opérations d’initiés, les sociétés et leurs statistiques en langage courant. Votre question devient une requête sur les données disponibles, pas une conversation ni un conseil en investissement.
Données de OSE IMMUNOTHERAPEUTICS uniquement. Pas de recherche web. Les statistiques globales d’un initié sont exclues.
Une recherche exécutée consomme un crédit, même sans résultat. Les erreurs et les questions non prises en charge ne consomment rien.
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; ABBV-230, an agonist antibody against ChemR23 to resolve chronic inflammation; and CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a new technology of bispecific checkpoint inhibitors targeting the PD1 receptor and other innovative targets. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
Source des informations de marché · Oct 19, 2026
Chronologie sur le marché · historique complet
1 achat4 ventes— cours de clôturebarre = volume usd, échelle √cliquez sur une période pour filtrer le tableau
| Initié | Type | Valeur · USD | Signaux | Détail |
|---|---|---|---|---|
| Alexis Peyroles | Autre | n.d. (Transaction sans contrepartie en espèces : la déclaration indique un prix nul (attribution, don, exercice)) | AMF |
| Didier Hoch | Exercice | $41.9K | AMF |
| Eric Leire | Exercice | $419.3K | AMF |
| MARYONNE HIANCE | Vente | $321.9K | AMF |
| ANNE-LAURE AUTRET-CORNET | Vente | $107.1K | AMF |
| MARYONNE HIANCE | Exercice | $38.4K | AMF |
| DOMINIQUE COSTANTINI | Exercice | $38.3K | AMF |
| Didier Hoch | AutreD (dérivé) | $38.4K | AMF |
| Didier Hoch | Vente | $49.3K | AMF |
| MARYONNE HIANCE | Vente | $343K | AMF |
| DOMINIQUE COSTANTINI | Achat | $246.8K | conv 59Premier en 12 mois | AMF |